---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-029085"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2026-06-17T20:15:20+00:00"
generated_at: "2026-06-17T20:23:35.220732+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Hepion shareholders approve 40x increase in equity plan shares to 8M at annual meeting

## Summary
- Elected directors Stetz, V. LoPriore, Purcell, Appajosyula, C. LoPriore with ~13.5M votes each.
- Ratified Grassi & Co. as auditors for FY2026: 18.1M for, 117K against, 223K abstain.
- Approved amendment to 2023 equity plan, increasing shares from 200K to 8M: 13.4M for, 209K against.
- Broker non-votes totaled 4.8M on director election and equity plan proposals.

## SEC filing metadata
- accession: 0001493152-26-029085
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2026-06-17T20:15:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315226029085/0001493152-26-029085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315226029085/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-029085
- JSON: https://secwatch.observer/filing/0001493152-26-029085.json
- Plain text: https://secwatch.observer/filing/0001493152-26-029085.txt

## Key facts
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. at the 2026-06-17 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: To approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. Votes For Votes Against Votes Abstained Broker Non-Vote 13,442,072 208,879 1,751 4,816,704
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000149315226029085/0001493152-26-029085-index.htm
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. at the 2026-06-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 18,128,998 116,985 223,423 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000149315226029085/0001493152-26-029085-index.htm
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Election of five director nominees: Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore at the 2026-06-17 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: To elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore. Name Votes For Withhold Broker Non-Vote Gary Stetz 13,498,755 153,947 4,816,704 Vincent LoPriore 13,492,507 160,195 4,816,704 Michael Purcell 13,186,912 465,790 4,816,704 Sireesh Appajosyula 13,503,469 149,233 4,816,704 Chase LoPriore 13,492,110 160,592 4,816,704
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000149315226029085/0001493152-26-029085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.